American Association for Cancer Research to Co-host Symposium on Cancer Molecular Diagnostic Test Advancements
WASHINGTON, D.C. — The American Association for Cancer Research (AACR) and AdvaMedDx will co-host a symposium titled “Transforming Cancer Care Through Diagnostics and Personalized Medicine,” on Tuesday, Oct. 29 at the Grand Hyatt, Washington, D.C.
The symposium will bring together a diverse group of stakeholders, including researchers, clinicians, patients and patient advocacy leaders, diagnostic industry representatives, and policymakers, to discuss how scientific progress in cancer genetics and genomics is enabling advances in the development of new molecular diagnostic tests.
AdvaMedDx is an organization that represents 70 of the world’s leading diagnostic manufacturers.
“Cancer diagnostics play a vital role in ensuring that treatments are more effective for all patients living with cancer,” said Charles L. Sawyers, M.D., president of the AACR and chair of the planning committee. “In addition to highlighting the scientific advances in cancer genetics and genomics that are supporting the development of new molecular diagnostic tests, the symposium will also look at the current regulatory and reimbursement environment for molecular diagnostics and how it is impacting patient access and safety to innovative diagnostics and personalized treatment options.”
Harold Varmus, M.D., director of the National Cancer Institute, will deliver the keynote talk on why diagnostics matter in this era of precision medicine and especially in cancer care.
A lunch discussion between National Institutes of Health Director Francis Collins, M.D., Ph.D., and U.S. Food and Drug Administration Commissioner Margaret Hamburg, M.D., (moderated by Dr. Sawyers) will provide these leaders with an opportunity to update their shared vision of personalized medicine and the scientific and regulatory infrastructure that is needed to support its growth.
The underlying goal of the symposium is to help advance the promise of personalized medicine, which leads to higher quality and longer lives for many cancer patients.